Below are downloadable forms required to become certified in the ZINBRYTA (daclizumab) REMS Program.

Materials for Prescribers

Click here to learn more about these resources. Download the:

Materials for Pharmacies

Click here to learn more about these resources. Download the:

Materials for Patient Counseling

Click here to learn more about these resources. Download the:

Adobe® Reader® is required to view all of these PDFs. If you do not have it installed, download it free here.

If you have any questions about the ZINBRYTA REMS Program or need help enrolling, call 1-800-456-2255.

Indication

ZINBRYTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of ZINBRYTA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Please see Prescribing Information, including BOXED WARNING, for additional information.